RESILIENCE helps you survive cancer with a strong heart
RESILIENCEH2020

RESILIENCE: a European Commission-funded project aimed at reducing the incidence of heart failure in cancer survivors

Cancer survivors are at high risk for cardiovascular complications. Anthracyclines are an extremely effective treatment against many cancer types, but they can induce cardiac toxicity resulting in chronic heart failure.

RESILIENCE tests a novel preventive intervention (remote ischemic conditioning) in patients at risk for anthracycline-induced cardiotoxicity. In addition, new diagnostic modalities will be used to identify anthracyclines-induced cardiotoxicity in its very early stages.

RESILIENCE counts on a multidisciplinary consortium with the active participation of patients.

News

adminresilience November 18 2022

RESILIENCE IN PORTUGAL

On November 2nd, RESILIENCE team traveled to Portugal to visit the two medical centers that…

adminresilience October 14 2022

Opening of new centers

We are glad to announce that in October 13th a new centers has joined the…

THE CHALLENGE:
Reduce the Heart Failure in Cancer Survivors

Thanks to the great scientific and medical advances, the prevalence of cancer survivors in increasing in Europe. However, cancer survivors are at high risk for cardiovascular complications. Among them, heart failure is especially worrisome. There is a strong need to reduce the burden of disability in cancer survivors and to increase their quality of life.

THE THERAPY:
Remote Ischemic Conditioning

Remote Ischemic Conditioning (RIC) is a phenomenon by which brief, reversible episodes of occlusion and re-occlusion in one organ (e.g. an arm) render remote organs resistant to injury.

CARDIAC MAGNETIC RESONANCE

Cardiac magnetic resonance (CMR) it is a technique without radiation, which is considered the gold-standard for the evaluation of cardiac anatomy, function and even tissue composition.

CLINICAL TRIAL SYNOPSIS

Multinational, prospective, proof of concept phase II, double-blinded, sham-controlled, randomized clinical trial (RCT) to evaluate the efficacy and safety of Remote Ischaemic Conditioning (RIC) in Non-Hodgkin lymphoma (NHL) patients receiving anthracyclines. Patients scheduled to undergo ≥5 chemotherapy cycles will be eligible.

WHY NON-HODGKIN LYMPHOMA

Non-Hodgkin Lymphoma (NHL) treatment includes the use of anthracyclines within a homogeneous combination chemotherapy. NHL are specially vulnerable to anthracycline-induced heart failure. NHL affects similarly women and men, and it it thus ideal to study gender differences in cardiotoxicity.

For Scientist

Read the most recent scientific advances in the field by RESILIENCE partners.

For General Public

Read the most recent newsletters, press releases, and other information about RESILIENCE in layperson´s language.

For Patients

Are you a patient participating in RESILIENCE? Here you will find useful information about the details of your participation, activities specifically designed for you. You will also be able to contact RESILIENCE researchers.

Partners

Logotipo Resilience

Are you a patient participating in RESILIENCE? Here you will find useful information about the details of your participation, activities specifically designed for you. You will also be able to contact RESILIENCE researchers.

In accordance with the provisions of Regulation (EU) 2016/679 on the protection of personal data of natural persons (GDPR), the personal information you have provided will be incorporated into the data processing systems of the Centro Nacional de Investigaciones Cardiovasculares Carlos III (F.S.P.) for the purpose of attending your registration application in the restricted area for patients participating in the RESILIENCE study. The legal basis for processing your personal data for this purpose is your explicit consent. Your personal data will not be disclosed to any recipients other than those to whom you authorise or when required by law to do so. You may exercise your rights of access, right to rectification, to object, to erasure, to restriction of processing, data portability and not to be subject to automated individual decision-making. To exercise these rights, as well as to obtain additional information about the processing of your personal data, you can consult the following link Terms and Conditions